ALDH1 is an independent prognostic factor for patients with stages II-III rectal cancer after receiving radiochemotherapy

British Journal of Cancer

Volumn 110, Issue 2, 2014, Pages 430-434

  Deng, Y ^a   Zhou, J ^a   Fang, L ^a   Cai, Y ^a   Ke, J ^a   Xie, X ^a   Huang, Y ^a   Huang, M ^a   Wang, J ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

ALDH1; cancer stem cell; neoadjuvant; rectal cancer

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; FLUOROURACIL; HERMES ANTIGEN; LGR5 PROTIEN; PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; LGR5 PROTEIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RECTUM CARCINOMA; TUMOR BIOPSY; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STEM CELL; CORRELATION ANALYSIS; HISTOPATHOLOGY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE TREATMENT; RECTUM RESECTION; UPREGULATION;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD44; CELL ADHESION MOLECULES, NEURONAL; CHEMORADIOTHERAPY; FEMALE; FETAL PROTEINS; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; PROGNOSIS; RECEPTORS, G-PROTEIN-COUPLED; RECTAL NEOPLASMS; RETINAL DEHYDROGENASE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84892934631     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.767     Document Type: Article

References (17)

1. Arcaroli JJ, Powell RW, Varella-Garcia M, McManus M, Tan AC, Quackenbush KS, Pitts TM, Gao D, Spreafico A, Dasari A, Touban BM, Messersmith WA (2012) ALDH\+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a gamma-secretase inhibitor and irinotecan in colorectal cancer. Mol Oncol 6: 370-381.
2. Avoranta ST, Korkeila EA, Ristamaki RH, Syrjanen KJ, Carpen OM, Pyrhonen SO, Sundstrom JT (2013) ALDH1 expression indicates chemotherapy resistance and poor outcome in node-negative rectal cancer. Hum Pathol 44: 966-974.
3. Boman BM, Wicha MS (2008) Cancer stem cells: a step toward the cure. J Clin Oncol 26: 2795-2799.
4. Deng YH, Pu XX, Huang MJ, Xiao J, Zhou JM, Lin TY, Lin EH (2010) 5-Fluorouracil upregulates the activity of Wnt signaling pathway in CD133-positive colon cancer stem-like cells. Chin J Cancer 29: 810-815.
5. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, Pickell K, Aguilar J, Lazetic S, Smith-Berdan S, Clarke MF, Hoey T, Lewicki J, Gurney AL (2008) Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 3: e2428.
6. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69: 3382-3389.
7. Iinuma H,Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J,Matsuda K, Fukushima R, Okinaga K, Sasako M, Mori M (2011) Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol 29: 1547-1555.
8. Kemper K, Prasetyanti PR, De Lau W, Rodermond H, Clevers H, Medema JP (2012) Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Stem Cells 30: 2378-2386.
9. Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L, Zlobec I (2010) Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 103: 382-390.
10. O'Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
11. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancerinitiating cells. Nature 445: 111-115.
12. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23: 8688-8696.
13. Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, O'Donoghue DP, Moriarty M, Fennelly D, Sheahan K (2005) Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 47: 141-146.
14. Sauer R, Becker H, Hohenberger W, Rodel C,Wittekind C, Fietkau R,Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731-1740.
15. Shenoy AK, Fisher RC, Butterworth EA, Pi L, Chang LJ, Appelman HD, Chang M, Scott EW, Huang EH (2012) Transition from colitis to cancer: high Wnt activity sustains the tumor-initiating potential of colon cancer stem cell precursors. Cancer Res 72: 5091-5100.
16. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D'Angelica M, Kemeny N, Lyden D, Rafii S (2008) CD133 expression is not restricted to stem cells, and both CD133\+ and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest 118: 2111-2120.
17. Sprenger T, Conradi LC, Beissbarth T, Ermert H, Homayounfar K, Middel P, Ruschoff J, Wolff HA, Schuler P, Ghadimi BM, Rodel C, Becker H, Rodel F, Liersch T (2013) Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival. Cancer 119: 26-35.